- Latest available (Revised)
- Point in Time (01/04/2016)
- Original (As made)
Version Superseded: 31/12/2020
Point in time view as at 01/04/2016.
There are outstanding changes not yet made by the legislation.gov.uk editorial team to The Medicines (Products for Human Use) (Fees) Regulations 2016. Any changes that have already been made by the team appear in the content and are referenced with annotations.
Changes and effects yet to be applied by the editorial team are only applicable when viewing the latest version or prospective version of legislation. They are therefore not accessible when viewing legislation as at a specific point in time. To view the ‘Changes to Legislation’ information for this provision return to the latest version view using the options provided in the ‘What Version’ box above.
3. In this Part—
“EU marketing authorisation” means—
a United Kingdom marketing authorisation granted by the licensing authority under Part 5 (marketing authorisations) of the Human Medicines Regulations;
a marketing authorisation granted by the competent authority of an EEA State other than the United Kingdom in accordance with the 2001 Directive; or
a European Union marketing authorisation; and
“relevant medicinal product” means a medicinal product for human use to which the provisions of the 2001 Directive apply.
4. Unless regulation 5 applies, the fee payable by a person with whom the licensing authority holds a meeting in order to provide scientific advice with a view to that person making an application for an EU marketing authorisation or an application for the variation of an EU marketing authorisation, is—
(a)£2,201, if the advice provided at that meeting consists of advice in connection with—
(i)quality development only; or
(ii)safety development only;
(b)£2,763, if the advice provided at that meeting consists only of advice in connection with clinical development;
(c)£3,061, if the advice provided at that meeting consists only of advice in connection with quality and safety development;
(d)£3,624, if the advice provided at that meeting consists of advice in connection with—
(i)quality and clinical development; or
(ii)safety and clinical development;
(e)£4,487, if the advice provided at that meeting consists of advice in connection with quality, safety and clinical development.
5.—(1) The fee payable by a person with whom the licensing authority holds a meeting to provide scientific advice in connection with the classification of a relevant medicinal product, is—
(a)£2,763, if the advice relates to a product which, if reclassified, will be available on general sale; and
(b)£3,624, if the advice relates to a product which, if reclassified, will be available without a prescription from a pharmacy.
(2) For the purposes of this regulation, a product is on general sale if it is a medicinal product subject to general sale within the meaning of regulation 5(1) of the Human Medicines Regulations (classification of medicinal products for general sale).
6. The fee payable by the holder of a marketing authorisation with whom the licensing authority holds a meeting in order to provide advice before the publication of advertising of a medicinal product by that holder's undertaking on whether that advertising conforms to the requirements of Title VIII of the 2001 Directive, is £2,201.
7.—(1) The fee payable by a person with whom the licensing authority holds a meeting in order to provide pharmacovigilance advice is—
(a)£3,624, in a case where the time taken by the licensing authority to prepare for and attend the meeting is more than six hours;
(b)£3,061, in any other case.
(2) The time taken by the licensing authority for the purposes of paragraph (1) shall be the total time spent by each individual engaged in preparing for or attending the meeting on behalf of the licensing authority.
8. The fee payable by the holder of one or more marketing authorisations with whom the licensing authority holds a meeting in order to provide advice on proposed changes to the labelling or the package leaflets of the medicinal products to which those authorisations relate, is £2,201.
9. The fee payable by the holder of a marketing authorisation with whom the licensing authority holds a meeting in order to provide regulatory advice to that person, is £2,763.
10.—(1) Unless paragraph (4) applies, the fee payable by a person specified in paragraph (2) with whom the licensing authority holds a meeting for a purpose specified in paragraph (3) is £4,451.
(2) A person who—
(a)is, or is to be, a sponsor of a clinical trial;
(b)manufactures medicinal products;
(c)is, or is to be, responsible for placing medicinal products on the market; or
(d)acts on behalf of, or provides advice or assistance to, a person referred to in sub-paragraphs (a) to (c),
is a specified person for the purpose of paragraph (1).
(3) A meeting referred to in paragraph (1) is for a specified purpose if it is held to provide advice in relation to—
(a)scientific or regulatory issues relating to the development of a medicinal product or a type of medicinal product;
(b)the design of pharmaceutical or pre-clinical tests, or clinical trials, for a medicinal product or a type of medicinal product;
(c)the management of risk in relation to a medicinal product or a type of medicinal product which is under development, or is being marketed in the European Union; or
(d)other scientific or regulatory issues relating to a medicinal product or a type of medicinal product after an EU marketing authorisation has been granted for that product or a product of that type.
(4) Paragraph (1) does not apply in the case of a meeting where the purpose of such a meeting is to provide only advice specified in regulations 4 to 9.
(5) In this regulation—
“Directive 93/42/EEC” means Council Directive 93/42/EEC concerning medical devices F1;
“medical device” has the same meaning as in Article 1(2)(a) of Directive 93/42/EEC;
“medicinal product” includes a substance incorporated in a medical device which, if used separately, may be considered to be a medicinal product as defined in Article 1(2) of the 2001 Directive;
“regulatory issues” means issues relating to the application of any EU instrument relating to EU marketing authorisations or to medical devices, or any enactment which implements such an instrument;
“risks” means any risk relating to the quality, safety or efficacy of a medicinal product as regards patients' health or public health, or any risk of undesirable effects on the environment;
“sponsor” shall be interpreted in accordance with regulation 3 (sponsor of a clinical trial) of the Clinical Trials Regulations F2;
and a reference to the development of a medicinal product or a type of medicinal product is a reference to development for the purposes of—
(a)obtaining an EU marketing authorisation, or making a variation to an EU marketing authorisation, for that product or a product of that type; or
(b)obtaining a design-examination certificate of the type mentioned in paragraph 4.3 of Annex II to Directive 93/42/EEC or a type-examination certificate of the type mentioned in paragraph 5 of Annex III to that Directive, for a medical device incorporating that product or a product of that type.
Textual Amendments
F1OJ No L 169, 12.7.1993, p1. This Directive has been amended by Directive 98/79/EC of the European Parliament and of the Council (OJ No L 331, 7.12.1998, p1), Directive 2000/70/EC of the European Parliament and of the Council (OJ No L 313, 13.12.2000, p22), Directive 2001/104/EC of the European Parliament and of the Council (OJ No L 6, 10.1.2002, p50), Regulation (EC) No 1882/2003 of the European Parliament and of the Council (OJ No L 284, 31.10.2003, p1) and Directive 2007/47/EC of the European Parliament and of the Council (OJ No L 247, 21.9.2007, p21).
F2Regulation 3 has been amended by S.I. 2006/1928.
11. All sums payable by way of fees under regulations 4 to 10 must be paid within a period of 14 days, commencing on the date of the written notice issued by the licensing authority requiring payment of those fees.
The Whole Instrument you have selected contains over 200 provisions and might take some time to download. You may also experience some issues with your browser, such as an alert box that a script is taking a long time to run.
Would you like to continue?
Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.
Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.
Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.
Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.
Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.
Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.
Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:
This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.
Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:
Click 'View More' or select 'More Resources' tab for additional information including: